Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Thursday after the company announced a proposed offering of its common stock.
Recursion Pharmaceuticals Inc (纳斯达克: RXRX)的股票周四交易较低,此前该公司宣布拟议发行普通股。
What Happened: Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering.
发生了什么事: Recursion宣布,拟以6.5美元/股向公众发行30,769,230股普通股。
The clinical-stage biotech company also said it plans to grant the underwriters a 30-day option to purchase up to an additional 4,615,384 of the shares being offered. All of the shares are being sold by Recursion.
这家临床阶段的生物技术公司还表示,计划向承销商提供30天购买额外的4,615,384股股票的选择权。所有股票均由Recursion出售。
Recursion expects to receive total gross proceeds of approximately $200 million. The offering is expected to close on or about June 28. Recursion had $296.3 million in cash and cash equivalents as of March 31.
Recursion希望获得约2亿美元的总募集资金。发行预计将于6月28日左右结束。截至3月31日,Recursion拥有2.963亿美元的现金及现金等价物。
Why It Matters: The proposed offering comes just days after Recursion held its annual investor day. NVIDIA Corp (NASDAQ:NVDA) CEO Jensen Huang made an appearance at the event to discuss the role AI will play in drug discovery and development in the future.
为什么它很重要: 这次拟议发行股票的消息发布仅数天之后,Recursion举行了年度投资者日活动。英伟达公司(NVDA纳斯达克)首席执行官Jensen Huang在活动中露面,讨论人工智能在未来药物发现和研究中的作用。
Recursion and Nvidia announced a collaboration last year to accelerate development of AI foundation models for biology. Nvidia also reported investments in multiple companies, including Recursion, in a 13-F filing with the SEC in February. According to the filing, Recursion is Nvidia's second-largest investment after Arm Holdings.
Recursion和Nvidia去年宣布了合作,加速基于生物学的人工智能基础模型的开发。Nvidia在2月份提交给美国证券交易委员会的13F申报文件中,还报告了对多家公司的投资,其中包括Recursion。根据该申报文件,Recursion是英伟达股票后的第二大投资。
RXRX Price Action: Recursion Pharmaceuticals shares were down 20.1% at $7.00 at the time of writing, according to Benzinga Pro.
RXRX股票行情: 据Benzinga Pro消息,Recursion Pharmaceuticals股票在撰写本文时下跌20.1%,报7.00美元。
Photo: Shutterstock.
照片:shutterstock。